Companies › Verismo Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SynKIR-110 Autologous T cells transduced with mesothelin-directed KIR-CAR | – | Phase 1 | Ovarian Cancer | Dec 2027 |
| SynKIR-310 Autologous T cells transduced with CD19 KIR-CAR | – | Phase 1 | B Cell Lymphoma | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05568680 | SynKIR-110 | Phase 1 | Ovarian Cancer | Oncology | Dec 2027 |
| NCT06544265 | SynKIR-310 | Phase 1 | B Cell Lymphoma | Oncology | Sep 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.